Tag: Saroglitazar Mg
Zydus completes EPICS-IIITM trial enrollment for Saroglitazar Mg in PBC treatment
Zydus Lifesciences achieves a milestone in its research by successfully enrolling participants for the EPICS-IIITM Phase 2b/3 trial, evaluating Saroglitazar Mg's efficacy in treating Primary Biliary Cholangitis (PBC), a rare autoimmune liver disease
Zydus Cadila’s Saroglitazar granted ‘Orphan Drug Designation’ by USFDA
Saroglitazar Mg is a potent and selective peroxisome proliferator-activated receptor alpha and gamma dual agonist used in the treatment of patients with Primary Biliary Cholangitis (PBC)........................